Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone
Year: 2026
Type: article
Abstract: Plain Language SummaryWhat is this summary about?This is a summary of a publication about the IKEMA clinical trial that was published in The Lancet Haematology in July 2024. The trial tested if a combination of cancer drugs (isatuximab plus carfilzomib and dexamethasone, or Isa-Kd for short) would help people with relapsed (when cancer returns after a period of improvement following treatment) or refractory (when cancer stops responding to treatment) multiple myeloma live longer. Isa-Kd was compared with a combination of carfilzomib and dexamethasone (or Kd for short) in this study. The IKEMA trial included participants who had been treated for their multiple myeloma before with other cancer medicines.How was the study in this summary conducted?This study included a total of 302 participants; 179 received Isa-Kd and 123 received Kd. The researchers measured overall survival, which is the total amount of time people lived during the study regardless of whether they died of cancer or from other causes. The researchers also measured how long people lived before their cancer got worse, once they stopped taking the IKEMA study treatments and started taking a new multiple myeloma treatment. The adverse events in participants who received at least 1 treatment were also measured.What are the key takeaways?People with relapsed and/or refractory multiple myeloma at study entry who received Isa-Kd continued to benefit from therapy after about 4.5 years of monitoring. People who received Isa-Kd were predicted to live about 13 months longer than people who received Kd, although the researchers could not rule out that the benefit was due to chance. People who received Isa-Kd also lived longer before their cancer got worse, once they started taking their next multiple myeloma treatment. Isa-Kd did not show any new safety concerns compared with previous studies.Clinical trial number: NCT03275285
Source: Future Oncology
Authors: Kwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Philippe Moreau
Institutions: University College London, University of California, San Francisco, National and Kapodistrian University of Athens, Translational Genomics Research Institute, City of Hope, Hospital Mãe de Deus, Centre Hospitalier Universitaire de Lille, University of Ostrava, University Hospital Ostrava, Charles University, Murdoch University, Samsung Medical Center, Sungkyunkwan University, Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, University Hospital Brno, Inserm, Institut Català d'Oncologia, Seoul National University, Seoul National University Hospital, Japanese Red Cross Medical Center, Sanofi (France), Centre Hospitalier Universitaire de Nantes
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Sanofi
OpenAlex ID: W7166317066
FWCI:
Cites:
Cited by:
Related to: